Cantor Fitzgerald downgraded Astria Therapeutics (ATXS) to Neutral from Overweight.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Is ATXS a Buy, Before Earnings?
- Astria Therapeutics announces final results from ALPHA-STAR trial
- Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment
- Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward
- Astria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright